Sanofi and Teva's collaboration to deliver inflammatory bowel disease treatment

Published: 4-Oct-2023

TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease by Sanofi and Teva Pharmaceuticals

Sanofi and Teva Pharmaceuticals, a US subsidiary of Teva Pharmaceutical Industries, have announced a collaboration to co-develop and co-commercialise asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.

Paul Hudson, CEO of Sanofi, said: “Anti-TL1As are a promising class of therapies, and we believe that TEV’574 could emerge as a best-in-class option for people living with serious gastrointestinal diseases. This collaboration strengthens our commitment to advancing innovative treatment options for inflammatory conditions with a high unmet need and bolsters our goal to be an industry leader in immunology.”

Richard Francis, President and CEO of, Teva, said: “This is a new era for Teva, and our robust, innovative pipeline is key to our Pivot to Growth strategy. This collaboration further validates the great science that Teva has to offer with our internally developed anti-TL1A. We are honoured to partner with Sanofi to bring their proven capabilities, leadership, and success in the immunology and gastroenterology space together with our capabilities to optimise development and global launches.”

This collaboration strengthens our commitment to advancing innovative treatment options

- Paul Hudson, CEO of Sanofi

Under the terms of the new collaboration agreement, Teva will receive an upfront payment of €469 million ($500 million) and up to €940 million ($1 billion) in development and launch milestones. Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement and Sanofi will lead the development of the Phase 3 programme.

Teva will lead commercialisation of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialisation in North America, Japan, other parts of Asia and the rest of the world. The transaction will become effective after customary closing conditions are met. Initial program results are expected to be available in 2024.

Inflammatory bowel disease (IBD) is the term for two conditions, Crohn’s disease and ulcerative colitis – characterised by chronic inflammation of the gastrointestinal (GI) tract. Prolonged inflammation results in damage to the GI tract. The common symptoms for both conditions are persistent diarrhoea, rectal bleeding, abdominal pain, fatigue, and weight loss. An estimated 10 million people worldwide live with IBD.

You may also like